Emerging therapies for noninfectious uveitis: What may be coming to the clinics

Jose R. Maya, Mohammad A. Sadiq, Liz J. Zapata, Mostafa Hanout, Salman Sarwar, Nithya Rajagopalan, Kathleen E. Guinn, Yasir J. Sepah, Quan Dong Nguyen

Research output: Contribution to journalReview article

18 Citations (Scopus)

Abstract

Corticosteroids along with other immunomodulatory therapies remain as the mainstay of treatment tor all patients with noninfectious uveitis (NIU). However, the systemic side effects associated with the long-term use of these drugs has encouraged the development of new therapeutic agents in recent times. This review article discusses upcoming therapeutic agents and drug delivery systems that are currently being used to treat patients with NIU. These agents mediate their actions by blocking specific pathways involved in the inflammatory process. Agents discussed in this review include full or recombinant monoclonal antibodies against interleukins such as IL-17 (secukinumab), IL-l (gevokizumab), and IL-6 (tocilizumab and sarilumab), antibody fragments against inflammatory cytokines such as TNF-α (ESBA 105) and T-cell inhibitors such as fusion proteins (abatacept), and next generation calcineurin inhibitors (voclosporin). In addition, administration of immune modulatory therapies using methods such as iontophoresis (EGP-437) and intravitreal injection (sirolimus) for the treatment of NIU' uveitis has also been discussed.

Original languageEnglish (US)
Article number310329
JournalJournal of Ophthalmology
Volume2014
DOIs
StatePublished - 2014

Fingerprint

Uveitis
Therapeutics
Iontophoresis
Immunoglobulin Fragments
Intravitreal Injections
Immunomodulation
Interleukin-17
Interleukins
Sirolimus
Drug Delivery Systems
Interleukin-6
Adrenal Cortex Hormones
Monoclonal Antibodies
Cytokines
T-Lymphocytes
Pharmaceutical Preparations
Proteins

ASJC Scopus subject areas

  • Ophthalmology

Cite this

Maya, J. R., Sadiq, M. A., Zapata, L. J., Hanout, M., Sarwar, S., Rajagopalan, N., ... Nguyen, Q. D. (2014). Emerging therapies for noninfectious uveitis: What may be coming to the clinics. Journal of Ophthalmology, 2014, [310329]. https://doi.org/10.1155/2014/310329

Emerging therapies for noninfectious uveitis : What may be coming to the clinics. / Maya, Jose R.; Sadiq, Mohammad A.; Zapata, Liz J.; Hanout, Mostafa; Sarwar, Salman; Rajagopalan, Nithya; Guinn, Kathleen E.; Sepah, Yasir J.; Nguyen, Quan Dong.

In: Journal of Ophthalmology, Vol. 2014, 310329, 2014.

Research output: Contribution to journalReview article

Maya, JR, Sadiq, MA, Zapata, LJ, Hanout, M, Sarwar, S, Rajagopalan, N, Guinn, KE, Sepah, YJ & Nguyen, QD 2014, 'Emerging therapies for noninfectious uveitis: What may be coming to the clinics', Journal of Ophthalmology, vol. 2014, 310329. https://doi.org/10.1155/2014/310329
Maya JR, Sadiq MA, Zapata LJ, Hanout M, Sarwar S, Rajagopalan N et al. Emerging therapies for noninfectious uveitis: What may be coming to the clinics. Journal of Ophthalmology. 2014;2014. 310329. https://doi.org/10.1155/2014/310329
Maya, Jose R. ; Sadiq, Mohammad A. ; Zapata, Liz J. ; Hanout, Mostafa ; Sarwar, Salman ; Rajagopalan, Nithya ; Guinn, Kathleen E. ; Sepah, Yasir J. ; Nguyen, Quan Dong. / Emerging therapies for noninfectious uveitis : What may be coming to the clinics. In: Journal of Ophthalmology. 2014 ; Vol. 2014.
@article{26c941bdb7cf445e9b98ac4f1a6fb8e6,
title = "Emerging therapies for noninfectious uveitis: What may be coming to the clinics",
abstract = "Corticosteroids along with other immunomodulatory therapies remain as the mainstay of treatment tor all patients with noninfectious uveitis (NIU). However, the systemic side effects associated with the long-term use of these drugs has encouraged the development of new therapeutic agents in recent times. This review article discusses upcoming therapeutic agents and drug delivery systems that are currently being used to treat patients with NIU. These agents mediate their actions by blocking specific pathways involved in the inflammatory process. Agents discussed in this review include full or recombinant monoclonal antibodies against interleukins such as IL-17 (secukinumab), IL-l (gevokizumab), and IL-6 (tocilizumab and sarilumab), antibody fragments against inflammatory cytokines such as TNF-α (ESBA 105) and T-cell inhibitors such as fusion proteins (abatacept), and next generation calcineurin inhibitors (voclosporin). In addition, administration of immune modulatory therapies using methods such as iontophoresis (EGP-437) and intravitreal injection (sirolimus) for the treatment of NIU' uveitis has also been discussed.",
author = "Maya, {Jose R.} and Sadiq, {Mohammad A.} and Zapata, {Liz J.} and Mostafa Hanout and Salman Sarwar and Nithya Rajagopalan and Guinn, {Kathleen E.} and Sepah, {Yasir J.} and Nguyen, {Quan Dong}",
year = "2014",
doi = "10.1155/2014/310329",
language = "English (US)",
volume = "2014",
journal = "Journal of Ophthalmology",
issn = "2090-004X",
publisher = "Hindawi Publishing Corporation",

}

TY - JOUR

T1 - Emerging therapies for noninfectious uveitis

T2 - What may be coming to the clinics

AU - Maya, Jose R.

AU - Sadiq, Mohammad A.

AU - Zapata, Liz J.

AU - Hanout, Mostafa

AU - Sarwar, Salman

AU - Rajagopalan, Nithya

AU - Guinn, Kathleen E.

AU - Sepah, Yasir J.

AU - Nguyen, Quan Dong

PY - 2014

Y1 - 2014

N2 - Corticosteroids along with other immunomodulatory therapies remain as the mainstay of treatment tor all patients with noninfectious uveitis (NIU). However, the systemic side effects associated with the long-term use of these drugs has encouraged the development of new therapeutic agents in recent times. This review article discusses upcoming therapeutic agents and drug delivery systems that are currently being used to treat patients with NIU. These agents mediate their actions by blocking specific pathways involved in the inflammatory process. Agents discussed in this review include full or recombinant monoclonal antibodies against interleukins such as IL-17 (secukinumab), IL-l (gevokizumab), and IL-6 (tocilizumab and sarilumab), antibody fragments against inflammatory cytokines such as TNF-α (ESBA 105) and T-cell inhibitors such as fusion proteins (abatacept), and next generation calcineurin inhibitors (voclosporin). In addition, administration of immune modulatory therapies using methods such as iontophoresis (EGP-437) and intravitreal injection (sirolimus) for the treatment of NIU' uveitis has also been discussed.

AB - Corticosteroids along with other immunomodulatory therapies remain as the mainstay of treatment tor all patients with noninfectious uveitis (NIU). However, the systemic side effects associated with the long-term use of these drugs has encouraged the development of new therapeutic agents in recent times. This review article discusses upcoming therapeutic agents and drug delivery systems that are currently being used to treat patients with NIU. These agents mediate their actions by blocking specific pathways involved in the inflammatory process. Agents discussed in this review include full or recombinant monoclonal antibodies against interleukins such as IL-17 (secukinumab), IL-l (gevokizumab), and IL-6 (tocilizumab and sarilumab), antibody fragments against inflammatory cytokines such as TNF-α (ESBA 105) and T-cell inhibitors such as fusion proteins (abatacept), and next generation calcineurin inhibitors (voclosporin). In addition, administration of immune modulatory therapies using methods such as iontophoresis (EGP-437) and intravitreal injection (sirolimus) for the treatment of NIU' uveitis has also been discussed.

UR - http://www.scopus.com/inward/record.url?scp=84901257021&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901257021&partnerID=8YFLogxK

U2 - 10.1155/2014/310329

DO - 10.1155/2014/310329

M3 - Review article

C2 - 24868451

AN - SCOPUS:84901257021

VL - 2014

JO - Journal of Ophthalmology

JF - Journal of Ophthalmology

SN - 2090-004X

M1 - 310329

ER -